Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Early Indian Promise For A Cut-Price CAR-T Therapy

Executive Summary

A faculty member at the Indian Institute of Technology and the founder of Indian venture ImmunoACT hopes to deliver an indigenously developed CAR-T therapy at a fraction of current treatment costs.

You may also be interested in...



IQVIA Exec On Putting India Firmly In IO Trials Reckoning

An IQVIA executive in Asia sees scope for India to figure routinely on the radar of sponsors for immuno-oncology trials and outlines how some gaps to get there can be plugged.

Coronavirus Update: Moderna Lifted By BARDA funding, Europe Looks For Exit Strategy, Vaccine Funds

Plus: Moleculin hopes to move 2-DG prodrug into clinic, India progresses niche COVID-19 defenses and more.

India 2019 – R&D Highs, Compliance Woes And Other Lows

2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125979

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel